On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
The health policy think tank urged seniors to shop carefully for prescription drug coverage during Medicare open enrollment, given skyrocketing premiums and wide variance in costs between plans.
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which ...
Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that ...
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results